PMID- 30291546
OWN - NLM
STAT- MEDLINE
DCOM- 20200505
LR  - 20200505
IS  - 1941-6636 (Electronic)
VI  - 50
IP  - 4
DP  - 2019 Dec
TI  - Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic 
      Cancer Patients; Retrospective Evaluation, Single Institution Experience.
PG  - 879-887
LID - 10.1007/s12029-018-0170-8 [doi]
AB  - OBJECTIVES: We retrospectively evaluate local control rate at 6 months and 1 year 
      in oligometastatic cancer patients treated with SBRT using CyberKnife. METHODS: 
      Total of 21 patients with 24 treatment sites from February 2014 till June 2017 
      who were treated with SBRT in our institution were included in this study. 
      RESULTS: Eleven patients were males, 10 patients were females, median age at 
      diagnosis was 63 years, and colorectal cancer is the most commonly diagnosed 
      cancer in 18 patients. The abdomino-pelvic lymph nodes were the commonest 
      treatment site in 11 (45.8%), average PTV volume of 46.4 cc. All the patients 
      received SBRT with average (BED) of 97 GY, 7 treatment sites received BED of 
      < 100GYgroup 1, and 17 received BED >/= 100GY group 2. No reported G3 or G4 acute 
      or chronic toxicity. The 6 months and 1 year local control (LC) were 95.8 and 
      88.2%, respectively. After a median follow-up of 16.8 months, 19(90.5%) patients 
      were alive; among them, local progression was observed in 1 (4.1%) treatment 
      site, while systemic progression in 4 (16.6%), and two (9.5%) patients died; they 
      had both local and systemic failures. The 1-year local PFS rate was 82%. In 
      univariate analysis, PTV volume was significantly correlated with LC rate at 
      6 months (p = 0.001), while the site of metastasis appeared to significantly 
      correlate with PFS (p = 0.03). CONCLUSION: SBRT using CyberKnife is feasible, 
      safe, and effective treatment for oligometastatic sites. Six months and 1 year 
      local control rate is 95.8 and 88.2% respectively in our patients cohort, 
      treatment regimens with higher BED resulting in better 1-year local PFS, although 
      it was not statistically significant. A larger cohort of patients and longer 
      follow up is required for better evaluation.
FAU - Alsuhaibani, Abdullah
AU  - Alsuhaibani A
AUID- ORCID: 0000-0002-2108-785X
AD  - Oncology Center, University Medical City, King Saud University, Riyadh, Saudi 
      Arabia. asuhaibani@gmail.com.
FAU - Elashwah, Ahmed
AU  - Elashwah A
AD  - Radiation oncology department King Faisal specialized hospital and research 
      center, Riyadh, Saudi Arabia.
AD  - Kasr Aleini center of clinical oncology and nuclear medicine (NEMROCK), Cairo 
      University, Cairo, Egypt.
FAU - Alkafi, Abdullah
AU  - Alkafi A
AD  - Radiation oncology department King Faisal specialized hospital and research 
      center, Riyadh, Saudi Arabia.
FAU - Constantinescus, Camelia
AU  - Constantinescus C
AD  - Radiation oncology department King Faisal specialized hospital and research 
      center, Riyadh, Saudi Arabia.
FAU - ALzorkany, Faisal
AU  - ALzorkany F
AD  - Radiation oncology department King Faisal specialized hospital and research 
      center, Riyadh, Saudi Arabia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Gastrointest Cancer
JT  - Journal of gastrointestinal cancer
JID - 101479627
SB  - IM
MH  - Adult
MH  - Aged
MH  - Colorectal Neoplasms/diagnostic imaging/mortality/pathology/*radiotherapy
MH  - Disease Progression
MH  - Feasibility Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Liver Neoplasms/diagnostic imaging/mortality/*radiotherapy/secondary
MH  - Lung Neoplasms/diagnostic imaging/mortality/*radiotherapy/secondary
MH  - Male
MH  - Middle Aged
MH  - Positron Emission Tomography Computed Tomography
MH  - Progression-Free Survival
MH  - Radiosurgery/adverse effects/instrumentation/*methods
MH  - Radiotherapy Planning, Computer-Assisted
MH  - Retrospective Studies
MH  - Survival Analysis
OTO - NOTNLM
OT  - Cancer
OT  - CyberKnife
OT  - Local control
OT  - Metastatic disease
OT  - Oligometastatic
OT  - Radiation
OT  - SBRT
OT  - Sterotactic
EDAT- 2018/10/07 06:00
MHDA- 2020/05/06 06:00
CRDT- 2018/10/07 06:00
PHST- 2018/10/07 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2018/10/07 06:00 [entrez]
AID - 10.1007/s12029-018-0170-8 [pii]
AID - 10.1007/s12029-018-0170-8 [doi]
PST - ppublish
SO  - J Gastrointest Cancer. 2019 Dec;50(4):879-887. doi: 10.1007/s12029-018-0170-8.